期刊文献+

骨保护素与代谢综合征 被引量:1

Osteoprotegerin and metabolic syndrome
原文传递
导出
摘要 骨保护素(OPG)是一种分泌型糖蛋白,属于肿瘤坏死因子受体超家族成员,不仅在骨代谢过程中起重要作用,而且是重要的血管调节因子,能够保护血管内皮细胞,抑制血管钙化和动脉粥样硬化。代谢综合征(MS)包括腹型肥胖、胰岛素抵抗、血脂异常、高血糖、高血压等。MS各组分均为心血管疾病的危险因素,2型糖尿病患者血OPG水平明显升高,但是OPG与MS其他各组分之间的关系目前还存在争议。 Osteoprotegcrin(OPG) is a secreted glycoprotein belonging to the tumor necrosis factor (TNF) receptor family. It has been identified as a regulator of bone resorption. Recent studies show that OPG also acts as an important regulatory molecule in the vasculature. It could not only protect the vascular endothelial cells, but also inhibit vascular calcification and atherosclerosis. Metabolic syndrome(MS) consists of central obesity,iusulin resistance, dyslipidemia, hyperglycemia and hypertension, etc. Each component of MS is a risk factor in cardiovascular diseases. Elevated levels of plasma OPG were reported in patients with type 2 diabetes mellitus,but there is conflicting evidence about whether there is a general relationship between circulating OPG levels and other components of MS.
出处 《国际内分泌代谢杂志》 2011年第4期274-276,共3页 International Journal of Endocrinology and Metabolism
关键词 骨保护素 动脉粥样硬化 糖尿病 代谢综合征 Osteoprotegerin Atherosclerosis Diabetes mellitus Metabolic syndrome
  • 相关文献

参考文献18

  • 1Shin J, Shin Y, Chung C. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 dia- betes. Diabetes Care ,2006,29 : 1664-1666.
  • 2Morony S,Tintyt Y,Zhang Z, et al. Osteoprotegerin inhibits vascu- lar calcification without affecting atherosclerosis in LDLr (-/-) mice. Circulation,2008,117:411-420.
  • 3Kahn R. Metabolic syndrome--what is the clinical usefulness? Lancet,2008,371 : 1892-1893.
  • 4Paola S, Federica C, Assunta P, et al. An increased osteoprote- gerin scrum release characterizes the early onset of diabetes melli- tus and may contribute to endothelial cell dysiunction. Am J Pathol, 2006,169 : 2236 -2244.
  • 5Yaturu S, Rains J, Jain SK. Relationship of elevated nsteoprote- gerin with insulin resistance, CRP,and TNF-a levels in men with type 2 diabetes. Cytokine ,2008,44 : 168-171.
  • 6Olsen P, Nguyen K, Wogensen L, et al. Calcification of human smooth muscle cells:associations with osteoprotegerin expression and acceleration by high-dose insulin. Am J Physiol Heart Cire Ph ysiol, 2007,292 : 1058 - 1064.
  • 7Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: in- creased amounts in diabetes and modifiable synthesis from vascu-lar smooth muscle cells by insulin and TNF-alpha. Diabetologia, 2005,48:561-568.
  • 8Jorgensen GM, Vind B, Nybo M, et al. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 di- abetes and obesity. Eur J Endocrino1,2009,16l :95-101.
  • 9Ugur-Ahun B, Ahun A. Circulation leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausN obese women. Arch Med Res,2007 ,38 :891-896.
  • 10Gannage-Yared MH, Fares F, Semaant M,et al. Circulation osteoprotegerin is correiated with lipid profile, insulin sensitivity, adi- ponectin amt sex steroids irt an ageing male population. Clin Endocrino1,2006 ,64 :652-658.

同被引文献23

  • 1刘燕萍,郑法雷.尿毒症患者血管钙化机制的研究进展[J].世界医学杂志,2004,8(13):7-10. 被引量:2
  • 2Block G, Port FK. Calcium phosphate metabolism and car- diovascttlar disease in patients with chronic kidney disease. Semin Dial, 2003, 16: 140-147.
  • 3Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcifi- cation in adult hemodialysis patients. A link between end- stage renal disease and cardiovascular disease? J Am Coll Cardiol, 2002, 39: 695-701.
  • 4Klassen PS, Lowrie EG, Reddan DN, et al. Association be- tween pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA, 2002, 287: 1548- 1555.
  • 5Reynolds JL, Joannides A J, Skepper JN, et al. Human vas- cular smooth muscle ceils undergo vesicle-mediated calcifica- tion in response to changes in extracellular calcium and phos- phate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol, 2004, 15 : 2857-2867.
  • 6Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res, 2004, 95: 560-567.
  • 7Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovas- cular mortality in patients on dialysis: a cross-sectional study. Lancet, 2003, 361: 827-833.
  • 8Moe SM, Reslerova M, Ketteler M, et al. Role of calcifica- tion inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int, 2005, 67: 2295-2304.
  • 9Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcifi- cation in adult hemodialysis patients. A link between end- stage renal disease and cardiovascular disease? J Am Coil Cardiol, 2(102, 39: 695-701.
  • 10Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res, 2000, 87: E10-E17.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部